Werewolf Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

HOWL$0.97-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for the and

Condensed Consolidated Statements of Operations (unaudited)

(amounts in thousands, except share and per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2024	2023	2024	2023
Revenue:
Collaboration revenue	$—	$5,897	$1,885	$18,442
Operating expenses:
Research and development	12,528	10,838	40,707	32,127
General and administrative	4,596	4,310	14,424	13,856
Total operating expenses	17,124	15,148	55,131	45,983
Operating loss	(17,124)	(9,251)	(53,246)	(27,541)
Other income:
Interest income	1,598	1,973	5,364	5,441
Interest expense	(1,244)	(1,002)	(3,389)	(2,129)
Loss on extinguishment of debt	—	—	(553)	—
Other income (expense), net	97	(5)	1,709	(1,136)
Total other income	451	966	3,131	2,176
Net loss	$(16,673)	$(8,285)	$(50,115)	$(25,365)
Net loss per common share, basic	$(0.38)	$(0.23)	$(1.17)	$(0.72)
Net loss per common share, diluted	$(0.38)	$(0.23)	$(1.19)	$(0.72)
Weighted-average common shares outstanding, basic	43,704,836	35,653,924	42,947,282	35,335,286
Weighted-average common shares outstanding, diluted	43,704,836	35,653,924	43,386,287	35,335,286

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.